HLA peptide therapy
US8715680B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 9, 2007 |
| Grant date | May 6, 2014 |
| Priority date | — |
| Expiry date | Dec 28, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.